Differential activation of ERK, p38, and JNK required for Th1 and Th2 deviation in myelin-reactive T cells induced by altered peptide ligand

被引:23
作者
Singh, RAK
Zhang, JWZ
机构
[1] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA
[2] Shanghai Med Univ 2, Chinese Acad Sci, Hlth Sci Ctr, Shanghai, Peoples R China
关键词
D O I
10.4049/jimmunol.173.12.7299
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Autoreactive T cells can be induced by altered peptide ligands to switch Th1 and Th2 phenotypes. The underlying molecular mechanism is critical for understanding of activation of autoreactive T cells and development of novel therapeutic strategies for autoimmune conditions. In this study, we demonstrated that analog peptides of an immunodominant epitope of myelin basic protein (residues 83-99) with alanine substitution at Val(86) and His(88) had a unique partial agonistic property in the induction of Th1 or Th2 deviation in MBP83-99-reactive T cell clones typical of Th0 phenotype. The observed. phenotypic switch involved differential activation of ERK, p38, and JNK MAPKs. More specifically, Th1 deviation induced by peptide 86V --> A (86A) correlated with enhanced p38 and JNK activities, while Th2 deviation by peptide 88H-A (88A) was associated with up-regulated ERK activity and a basal level of p38 and JNK activity. Further characterization revealed that a specific inhibitor for ERK selectively prevented Th2 deviation of MBP83-99-specific T cells. Conversely, specific inhibitors for p38 and JNK blocked Th1 deviation in the same T cell preparations induced by peptide 86A. The findings have important implications in our understanding of regulation of ERK, p38, and JNK by altered peptide ligands and their role in cytokine regulation and phenotype switch of autoreactive T cells.
引用
收藏
页码:7299 / 7307
页数:9
相关论文
共 47 条
[11]   Organization and regulation of mitogen-activated protein kinase signaling pathways [J].
Garrington, TP ;
Johnson, GL .
CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :211-218
[12]   Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals [J].
Hermans, G ;
Stinissen, P ;
Hauben, L ;
VandenBergLoonen, E ;
Raus, J ;
Zhang, JW .
ANNALS OF NEUROLOGY, 1997, 42 (01) :18-27
[13]   Multiple sclerosis:: expression of CD1a and production of IL-12 p70 and IFN-γ by blood mononuclear cells in patients on combination therapy with IFN-β and glatiramer acetate compared to monotherapy with IFN-β [J].
Hussien, Y ;
Sanna, A ;
Söderström, M ;
Link, H ;
Huang, YM .
MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (01) :16-25
[14]   T cell receptor antagonism in vivo, at last [J].
Jameson, SC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) :14001-14002
[15]   T-CELL RECEPTOR ANTAGONISTS AND PARTIAL AGONISTS [J].
JAMESON, SC ;
BEVAN, MJ .
IMMUNITY, 1995, 2 (01) :1-11
[16]   Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial [J].
Kappos, L ;
Comi, G ;
Panitch, H ;
Oger, J ;
Antel, J ;
Conlon, P ;
Steinman, L .
NATURE MEDICINE, 2000, 6 (10) :1176-1182
[17]  
Kozovska M, 1998, EUR J IMMUNOL, V28, P1894, DOI 10.1002/(SICI)1521-4141(199806)28:06<1894::AID-IMMU1894>3.0.CO
[18]  
2-W
[19]   Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex [J].
Krogsgaard, M ;
Wucherpfennig, KW ;
Canella, B ;
Hansen, BE ;
Svejgaard, A ;
Pyrdol, J ;
Ditzel, H ;
Raine, C ;
Engberg, J ;
Fugger, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (08) :1395-1412
[20]   THE STRESS-ACTIVATED PROTEIN-KINASE SUBFAMILY OF C-JUN KINASES [J].
KYRIAKIS, JM ;
BANERJEE, P ;
NIKOLAKAKI, E ;
DAI, TA ;
RUBIE, EA ;
AHMAD, MF ;
AVRUCH, J ;
WOODGETT, JR .
NATURE, 1994, 369 (6476) :156-160